Continued Drug Counterfeiting
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
2010 Commonwealth Games ~ 2010 Nobel Prizes ~ Sachin Tendulkar ~ Rajasthan Royals ~ Kings XI Punjab ~ Sushil Kumar ~ Deepika Kumari ~ Somdev Devvarman ~ HR Bhardwaj
Home / India News / 2007 / May / May 31, 2007
Continued Drug Counterfeiting Creates Significant Scope for Implementation of RFID in European Pharmaceutical Markets

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

Manmohan Singh to campaign in Bihar today

FBI failed to act on Headley's wife's terror link expose 3 yrs before Mumbai attacks

Craven's horror flicks 'were inspired by real stories'

RBI will intervene if inflows turn lumpy: Subbarao

Enforcement Directorate issues 'Look Out Circular' against Lalit Modi

Now, laser technology that destroys tumours using heat

Waist size, not BMI can foretell cardiovascular risk in children

Continued Drug Counterfeiting Creates Significant Scope for Implementation of RFID in European Pharmaceutical Markets

Mumbai, Maharashtra, India

The use of radio frequency identification (RFID) by Europe's pharmaceutical industry will continue to be driven by increasing counterfeit products in the market. Such counterfeiting is largely due to deficiencies in the supply chain and the legalised parallel trade in pharmaceuticals between EU member nations.

Frost & Sullivan ( finds that the European Markets for RFID in Pharmaceuticals earned revenues of $18.0 million in 2005 and estimates this to reach $464.8 million in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Markets for RFID in Pharmaceuticals (M043 - 48) then send an e-mail to Shwetha Thomas - Corporate Communications at with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"Globally, about five to eight per cent of prescription drugs are counterfeit, which is a big liability for pharma companies," notes Frost & Sullivan Research Analyst V. Sriram. "The absence of integration across the supply chain and the inability to track products at every stage has intensified this trend, while creating a real and urgent need for RFID."

Despite the tremendous scope for the use of RFID to track and manage products in the pharmaceutical industry, the lack of interoperability and harmonisation of standards remains a key issue. EU member nations will have to arrive at a consensus so that even as the initial cost of implementation is minimised, long-term sustainability can be achieved.

"Though 2D data matrix is perceived to be a better choice than RFID, the latter does not require line-of-sight and can scan multiple products at any given point of time, when compared to two dimensional bar codes," adds Mr. Sriram. "Hence, misconceptions about RFID and interoperability concerns need to be alleviated and uncertainties about the effectiveness of RFID fully addressed."

At the same time, RFID vendors need to keep themselves abreast of the regulatory and technological requirements of various countries and work closely with government agencies to ensure a smooth transition from bar codes to RFID. However, in the short term, companies cannot afford to dispense with bar codes and will need to adopt an informed approach towards implementing RFID.

European Markets for RFID in Pharmaceuticals is part of the Healthcare & Life Sciences IT Subscription which also includes research in the following markets: European Patient E-booking Systems Markets, Healthcare Applications of Smart Cards in Europe, European Patient Administration Systems Market and Solutions Supporting Pharmaceutical Distribution Channels in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit

European Markets for RFID in Pharmaceuticals
M043 - 48

Source: Frost & Sullivan (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.

Suggested pages for your additional reading on Facebook

© 2000-2017 All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us